Cargando…

A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity

Here, we describe the chemical synthesis and biological activity of a new Doxycycline derivative, designed specifically to more effectively target cancer stem cells (CSCs). In this analog, a myristic acid (14 carbon) moiety is covalently attached to the free amino group of 9-amino-Doxycycline. First...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ózsvári, Béla, Magalhães, Luma G., Latimer, Joe, Kangasmetsa, Jussi, Sotgia, Federica, Lisanti, Michael P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523513/ https://www.ncbi.nlm.nih.gov/pubmed/33042796 http://dx.doi.org/10.3389/fonc.2020.01528

Ejemplares similares

Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2018)

Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2019)

Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs)
por: Fiorillo, Marco, et al.
Publicado: (2019)

Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2017)

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
por: Sotgia, Federica, et al.
Publicado: (2018)

Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2017)

Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy
por: Ozsvari, Bela, et al.
Publicado: (2017)

Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast
por: Ozsvari, Bela, et al.
Publicado: (2017)

Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs)
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2017)

Cancer stem cells (CSCs): metabolic strategies for their identification and eradication
por: De Francesco, Ernestina M., et al.
Publicado: (2018)

Hallmarks of the cancer cell of origin: Comparisons with “energetic” cancer stem cells (e-CSCs)
por: Sotgia, Federica, et al.
Publicado: (2019)

A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis
por: Ozsvari, Bela, et al.
Publicado: (2017)

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds
por: Ózsvári, Béla, et al.
Publicado: (2020)

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)
por: Fiorillo, Marco, et al.
Publicado: (2016)

Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study
por: Scatena, Cristian, et al.
Publicado: (2018)

“Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy
por: Fiorillo, Marco, et al.
Publicado: (2019)

Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways
por: Bonuccelli, Gloria, et al.
Publicado: (2018)

High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy
por: Fiorillo, Marco, et al.
Publicado: (2021)

Azithromycin and Roxithromycin define a new family of “senolytic” drugs that target senescent human fibroblasts
por: Ozsvari, Bela, et al.
Publicado: (2018)

Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito‐stemness and ribo‐stemness features
por: Peiris‐Pagès, Maria, et al.
Publicado: (2019)

Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose
por: Peiris-Pagès, Maria, et al.
Publicado: (2015)

MitoTracker Deep Red (MTDR) Is a Metabolic Inhibitor for Targeting Mitochondria and Eradicating Cancer Stem Cells (CSCs), With Anti-Tumor and Anti-Metastatic Activity In Vivo
por: Sargiacomo, Camillo, et al.
Publicado: (2021)

Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy
por: Lamb, Rebecca, et al.
Publicado: (2015)

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity
por: Bonuccelli, Gloria, et al.
Publicado: (2016)

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease
por: Lamb, Rebecca, et al.
Publicado: (2015)

Cancer stem cells (CSCs), cervical CSCs and targeted therapies
por: Huang, Ruixia, et al.
Publicado: (2016)

Pancreatic CSCs and microenvironment
por: Ilmer, Matthias, et al.
Publicado: (2015)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Novel Metabolic Approaches Targeting Cancer Cells
por: Sebestyén, Anna, et al.
Publicado: (2023)

Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”
por: Fiorillo, Marco, et al.
Publicado: (2015)

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells
por: Lamb, Rebecca, et al.
Publicado: (2015)

Design and Characterization of Myristoylated and Non-Myristoylated Peptides Effective against Candida spp. Clinical Isolates
por: Bugli, Francesca, et al.
Publicado: (2022)

ATLAS computing on CSCS HPC
por: Filipcic, Andrej, et al.
Publicado: (2015)

ATLAS computing on CSCS HPC
por: Hostettler, Michael Artur, et al.
Publicado: (2015)

Myristoylation versus SRP
por: LeBrasseur, Nicole
Publicado: (2005)

Data on the calcium-induced mobility shift of myristoylated and non-myristoylated forms of neurocalcin delta
por: Viviano, Jeffrey, et al.
Publicado: (2016)

CSCs: regenerating optimism for osteosarcoma treatment
por: Levin, Adam S.
Publicado: (2018)

ALDH1A3 in CSCs
por: Sullivan, Kelly E., et al.
Publicado: (2017)

Eradication of CSCs: the roadmap for curing cancer
por: Romano, Simona, et al.
Publicado: (2020)

Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction
por: Lamb, Rebecca, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jioa8m2c86vtiptfkr7at4mr75